 - Administration of a product possibly containing RSV-neutralizing antibody within 30 days prior to enrollment or current administration includes, but is not restricted to, the following: RSV hyperimmunoglobulin, polyclonal intravenous immunoglobulin, cytomegalovirus hyperimmunoglobulin, varicella zoster hyperimmunoglobulin 